Knowing How Injection Volumes Impact Delivery Options

Why It Matters

Understanding how injection volume drives device choice enables pharma companies to redesign therapies for self‑administration, boosting patient adherence and lowering overall treatment costs.

Key Takeaways

• Injection volume decisions hinge on drug pharmacokinetic requirements.
• Constant flow drugs may still require infusion despite larger volumes.
• Reformulating enables subcutaneous delivery, reducing reliance on IV.
• Dosing interval extensions shift preference to infusion or on-body devices.
• Volumes above 5 ml facilitate less frequent, patient‑friendly dosing.

Summary

The panel discussed how the volume that can be self‑administered determines whether a therapy is delivered via a pre‑filled syringe (PFS), an autoinjector, or an infusion system.

Speakers emphasized that the deciding factor is the drug’s pharmacokinetic profile. Antibodies that merely need to reach systemic circulation can tolerate larger subcutaneous volumes, while agents requiring a steady plasma concentration may still need infusion. Reformulating biologics for subcutaneous injection is already reshaping the market, moving many IV products to on‑body or autoinjector platforms.

A cited review by Andreas Schneider highlighted that when devices allow dosing intervals to stretch—from weekly to monthly or quarterly—patients increasingly favor on‑body injectors or infusion pumps. Volumes exceeding roughly 5 ml make such extended intervals feasible, expanding the therapeutic window for self‑administration.

For manufacturers, these trends signal a need to align formulation, device engineering, and dosing schedules with patient convenience. Successfully shifting high‑volume, long‑interval therapies to self‑injectable formats can reduce healthcare costs and improve adherence.

Original Description

In this segment of the Drug Delivery Leader Live online event, Injected, Infused, or Implanted: A Penetrating Look At Patient Centricity, Chief Editor Tom von Gunden relays an audience question about how to decide if injection volumes dictate delivery via prefilled syringe versus autoinjector. Panelists Jonathan Amaya-Hodges, Fran DeGrazio, and Beate Bittner comment on an expanded range of options, including infusion systems and on-body injectors.

See more at https://www.drugdeliveryleader.com/